Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%
Source: The Asco Post, October 2023
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III to IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab.
These and other results of the analyses were presented as a proffered paper at the European Society of Medical Oncology (ESMO) Congress 2023 by Sapna P. Patel, MD, Chair of the SWOG Melanoma Committee and Associate Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center (Abstract LBA48). Dr. Patel is also the principal investigator of the S1801 trial.
“The pathologic responses seen in S1801 highlight the potential for single-drug immunotherapy to achieve results that we know are important for individual patient outcomes, namely the demonstration of a favorable pathologic response after a few doses of treatment,” Dr. Patel said.